Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525343 · ClinicalTrials.gov registry record
Avonex 15 Year Long Term Follow-up Study
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 122
- Enrollment target
NCT00525343 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 122 participants.
The verdict
NCT00525343 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 122 participants
- Enrollment target
Study Summary
The Avonex Fifteen-year Long-term Follow-up of Patients with Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs (ASSURANCE), was a single-time-point evaluation of patients conducted 15 years after the pivotal MSCRG study, evaluated the impact of IM IFNβ-1a treatment on long-term disability and Quality of Life outcomes in patients who completed 2 years in a previous Multiple Sclerosis Collaborative Research Group (MSCRG) study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525343
The ClinicalTrials.gov registry entry for NCT00525343 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00525343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00525343 about?
NCT00525343 is a clinical study titled "Avonex 15 Year Long Term Follow-up Study". The Avonex Fifteen-year Long-term Follow-up of Patients with Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs (ASSURANCE), was a single-time-point evaluation of patients conducted 15 years after the pivotal MSCRG study, evaluated the impact of IM I...
What is the current status of trial NCT00525343?
This trial is currently completed. The enrollment target is 122 participants. The study started on 2007-03. Estimated completion is 2008-09.
Who is sponsoring clinical trial NCT00525343?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.